![]() ![]() Head here to find out more and to get in touch. At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. "These funds will allow us to continue to support the commercial scaling up of our core technologies, expand our Kamaptive programme, which is focussed on large markets with significant growth potential, and develop our endoscopic suite of products for roll out on a global basis."Ĭenkos Securities PLC and Numis Securities Limited are acting as joint bookrunners and joint brokers for the three fundraises, Creo Medical added.īy Greg Rosenvinge, Alliance News reporterĬomments and questions to 2023 Alliance News Ltd. Creo Medical are dedicated to improving patient outcomes by applying advanced energy to the emerging field of surgical endoscopy, and we are doing so in an ever-increasing number of countries worldwide. CREO MEDICAL GROUP PLC CREO Stock London Stock Exchange Home > News and Prices > Prices and Markets > Creo Medical Group PLC Creo Medical Group PLC 123k Views Company page Our story Webcasts Trade recap Fundamentals Analysis Equity What's this Price (GBX) 29.30 1.03 (0.30) IQE ORD 1P Track 1 instrument Open / Last close 29.80 / 29. "We have seen excellent progress across our clinical adoption, Pioneer training programme, new product launches and partnering projects, and our Kamaptive partnerships with Intuitive and CMR Surgical, where our products are being adapted for use with robotic-assisted surgical platforms, continue to progress well. ![]() "Over the last year we have demonstrated rapid growth in the core technology and product revenues coming out of the pandemic," said Chief Executive Officer Craig Gulliford. In February the company announced the issue of 13,136,800 new Ordinary shares through subscription. This is alongside providing the company means to break even in its cash flow towards profitability and increased balance sheet strength. Creo Medical has conducted a placing, subscription, and open offer raising a total of £33.7mln. Medicare supplement plans (also known as Medigap) are a totally different concept than the Medicare Advantage plans familiar to you. The number of shares to be issued under the placing and subscription was not disclosed, while it said up to 26.0 million new shares would be issued under the open offer.Ĭreo Medical said the proposed fundraise will be used to progress its development and commercialisation plans for its electrosurgical devices, which it claims are "minimally invasive". Creo Medical’s pioneering products are used worldwide, providing: Patients with improved treatment options, focused on enhancing quality of life. Shares in Creo Medical plunged 18% to 22.88p in London on Thursday morning.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |